Thieno[2,3-b]pyridine compounds potently inhibit prostate cancer growth and motility
Thieno[2,3-<i>b</i>]pyridines therefore represent a potential therapy for prostate cancer, even when current therapies have failed.
Authors
- Paul Laissue (ORCID: https://orcid.org/0000-0003-4180-4796)
- Greg N. Brooke
- Charlotte L. Bevan (ORCID: https://orcid.org/0000-0002-7533-0552)
- Ralf M. Zwacka (ORCID: https://orcid.org/0000-0003-2821-0387)
- Metodi V. Metodiev (ORCID: https://orcid.org/0000-0001-6810-0719)
- David Barker (ORCID: https://orcid.org/0000-0002-3425-6552)
- Damien A. Leach (ORCID: https://orcid.org/0000-0003-3203-9826)
- Mohammad Alkheilewi
- Lisa I. Pilkington (ORCID: https://orcid.org/0000-0002-9292-3261)
- Jóhannes Reynisson (ORCID: https://orcid.org/0000-0003-4174-9512)
- Andrea Mohr (ORCID: https://orcid.org/0000-0002-4295-0341)
- M. Van Rensburg
Institutions
- University of Essex (GB)
- University of Auckland (NZ)
- Te Pūnaha Matatini
- Imperial College London (GB)
- Keele University (GB)
- MacDiarmid Institute for Advanced Materials and Nanotechnology (NZ)
Publication Details
- Journal
- Endocrine Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1530/eo-24-0082
- Primary Topic
- Synthesis and Characterization of Heterocyclic Compounds
- Type
- article
- Field-Weighted Citation Impact
- 0.00